Polycythemia vera (PV)
Drug research and approvals for polycythemia vera (PV): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 19 studies of polycythemia vera (PV) are recruiting on ClinicalTrials.gov, Health Canada has authorized 21 drug trials for it since 2013, FDA has 9 approved and 12 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 19
- Trials authorized in Canada: 21
- FDA orphan approvals: 9
- EU medicines: 1
- A Study of Ropeg-Interferon in People With Polycythemia VeraNCT07886801 · Phase 2 · Memorial Sloan Kettering Cancer Center · starts Oct 30, 2026
- Standardized Documentation and Assessments for Polycythemia Vera: A Quality Improvement InitiativeNCT07734272 · Not applicable · Massachusetts General Hospital · starts Sep 11, 2026
- Study to Assess Safety and Preliminary Efficacy of Orally Administered JBI-802 in Subjects With Essential…NCT07612280 · Phase 1 / Phase 2 · Jubilant Therapeutics Inc. · starts Oct 21, 2024
- Study of ZE74-0282 in Patients With JAK2 V617F- or Calreticulin-Mutated Hematologic DisordersNCT07529951 · Phase 1 · Eilean Therapeutics · starts Jun 1, 2026
- A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsNCT07469891 · Phase 1 · Prelude Therapeutics Incorporated · starts Apr 29, 2026
- A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PVNCT07445893 · Not applicable · Duan Minghui · starts Apr 2, 2026
- INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)NCT07429266 · Phase 3 · Ono Pharmaceutical Co., Ltd. · starts May 25, 2026
- MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With…NCT07362225 · Not reported · MPN Research Foundation · starts Sep 26, 2025
- Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia VeraNCT07232290 · Phase 2 · Chengdu Zenitar Biomedical Technology Co., Ltd · starts Sep 23, 2025
Approved 4
- RuxolitinibTyrosine-protein kinase JAK1 inhibitor
- Ropeginterferon alfa-2bInterferon alpha/beta receptor positive modulator
- MomelotinibTyrosine-protein kinase JAK1 inhibitor
- PacritinibTyrosine-protein kinase JAK2 inhibitor
Phase 3 8
- HydroxyureaRibonucleoside-diphosphate reductase RR1 inhibitor
- AspirinCyclooxygenase inhibitor
- Peginterferon alfa-2aInterferon alpha/beta receptor agonist
- Peginterferon alfa-2bInterferon alpha/beta receptor agonist
- Interferon alfa
- AnagrelidePhosphodiesterase 3 inhibitor
- PipobromanDNA inhibitor
- GivinostatHistone deacetylase inhibitor
Phase 2 12 of 18
- ImatinibTyrosine-protein kinase ABL inhibitor
- PrednisoneGlucocorticoid receptor agonist
- LestaurtinibTyrosine-protein kinase receptor FLT3 inhibitor
- NavtemadlinTumour suppressor p53/oncoprotein Mdm2 inhibitor
- IdasanutlinTumour suppressor p53/oncoprotein Mdm2 inhibitor
- LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- MethotrexateDihydrofolate reductase inhibitor
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- PomalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- ClopidogrelPurinergic receptor P2Y12 antagonist
- VorinostatHistone deacetylase 1 inhibitor
Phase 1 or earlier 9
- XL-019Tyrosine-protein kinase JAK2 inhibitor
- Arsenic trioxideThioredoxin reductase 1 inhibitor
- CytarabineDNA inhibitor
- DaunorubicinDNA topoisomerase II alpha inhibitor
- PanobinostatHistone deacetylase inhibitor
- UmbralisibPI3-kinase p110-delta subunit inhibitor
- DurvalumabProgrammed cell death 1 ligand 1 inhibitor
- AcetylcysteineGlutathione precursor
- Ascorbic acidSupplement
How its trials ended
228 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 72 whose ending is known, 44% met their primary endpoint, 8% missed it and 47% stopped early.
- Ongoing7533%
- Completed, result not reported7131%
- Met its primary endpoint3214%
- Stopped: other or unclear198%
- Status unknown104%
- Missed its primary endpoint63%
- Stopped: enrollment or feasibility52%
- Stopped: sponsor or business decision52%
- Stopped: lack of efficacy42%
- Stopped: safety1<1%
| Sep 17, 2026 | A phase 2/3, randomized, open-label, active-comparator-controlled, parallel-group multicenter study to evaluate the safety and efficacy of bomedemstat…Bomedemstat (MK-3543) | Merck & Co. (MSD) | Pending |
| Apr 15, 2026 | A phase 3 randomized, double-blind, placebo-controlled global study of sapablursen in polycythemia veraSapablursen (ONO-0530, isis 702843) | Ono Pharmaceutical | Pending |
| Jun 27, 2024 | An open label, multi-center, phase IV rollover protocol for patients who have completed a prior global novartis or incyte sponsored ruxolitinib (INC424) study…Ruxolitinib (INC424) | Novartis Pharmaceuticals | Ongoing |
| Jan 12, 2024 | Randomized, open-label, multicenter phase 3 study to assess the efficacy and safety of givinostat versus hydroxyurea in JAK2V617F-positive high-risk…Givinostat (ITF2357) / Hydroxyurea | Italfarmaco | Closed |
| Feb 2, 2023 | A phase IIIb, single-arm, multicenter study to access efficacy, safety, and tolerability of ropeginterferon ALFA-2B-njft (P1101) in adult patients with…Ropeginterferon ALFA-2B-NJFT (P1101) | PharmaEssentia | Ongoing |
| Apr 20, 2022 | A phase 3 study of the hepcidin mimetic rusfertide (PTG-300; TAK-121) in patients with polycythemia veraRusfertide (PTG-300, TAK-121) | Takeda Pharmaceuticals USA | Ongoing |
| Jan 12, 2022 | A phase 2a, randomized, open-label study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of isis 702843 administered to…Sapablursen (isis 702843) | Ionis Pharmaceuticals | Closed |
| Nov 29, 2019 | A randomized, controlled phase 3 study of pacritinib versus physician's choice in patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or…Pacritinib (SB1518) / Ruxolitinib / Hydroxyurea / Danazol | Sobi | Ongoing |
| Nov 13, 2019 | A randomized, double-blind, phase 3 study to evaluate the activity of momelotinib (MMB) versus danazol (DAN) in symptomatic, anemic subjects with primary…Momelotinib (MMB) / Danazol | Sierra Oncology | Ongoing |
| Jul 27, 2018 | A two-part, randomized, open-label, multicenter, phase 2a/2b study of the efficacy, safety, pharmacokinetics, and pharmacodynamics of KRT-232 compared to…KRT-232 / Ruxolitinib | Kartos Therapeutics Inc | Closed |
| Aug 28, 2026 | MimryloTreatment of erythrocytosis in adults with polycythemia vera (PV) | Takeda Development Center Americas, Inc. (a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A., Inc.) | Approved |
| May 1, 2026 | Jakafi XRTreatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea | Incyte Corporation | Approved |
| May 1, 2026 | Jakafi XRTreatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential… | Incyte Corporation | Approved |
| Sep 15, 2023 | OjjaaraTreatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and… | GlaxoSmithKline | Approved |
| Feb 28, 2022 | VonjoTreatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia)… | Sobi, Inc. | Approved |
| Nov 12, 2021 | BesremiTreatment of adults with polycythemia vera | PharmaEssentia | Approved |
| Aug 16, 2019 | InrebicINREBIC® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or… | Impact Biomedicines, Inc. a wholly-owned subsidiary of Celgene Corporation | Approved |
| Dec 4, 2014 | JakafiTreatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. | Incyte Corporation | Approved |
| Nov 16, 2011 | JakafiTreatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis… | Incyte Corporation | Approved |
| Jan 22, 2026 | Recombinant fully human IgG1 monoclonal antibodyTreatment of polycythemia vera | mAbTree Biologics AG | Designated |
| Aug 26, 2025 | Synthetic 19-mer peptide nucleic acid oligomer consisting…Treatment of polycythemia vera | Vanda Pharmaceuticals Inc. | Designated |
| Dec 19, 2024 | Synthetic 2-O-methoxyethyl phosphorothioate…Treatment of polycythemia vera | Vanda Pharmaceuticals Inc | Designated |
| Aug 5, 2024 | SapablursenTreatment of polycythemia vera (PV) | Deciphera Pharmaceuticals, LLC | Designated |
| Feb 8, 2024 | Recombinant humanized monoclonal antibody targeting…Treatment of Polycythemia Vera | Disc Medicine, Inc. | Designated |
| Feb 24, 2022 | Synthetic double-stranded siRNA oligonucleotide directed…Treatment of Polycythemia Vera (PV) | Silence Therapeutics plc | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Feb 15, 2019 | BesremiRopeginterferon alfa-2b | AOP Orphan Pharmaceuticals GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA